



## **Heron Therapeutics to Present at the Oppenheimer 25th Annual Healthcare Conference**

December 2, 2014

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Dec. 2, 2014-- Heron Therapeutics, Inc. (NASDAQ:HRTX), a biotechnology company, announced today that Barry D. Quart, Pharm.D., Chief Executive Officer of Heron Therapeutics, will present at the Oppenheimer 25th Annual Healthcare Conference on Wednesday, December 10, 2014 at 2:10 p.m. ET in New York City.

A live webcast of this presentation will be available on the Company's website at [www.herontx.com](http://www.herontx.com) in the Investors section. A replay of the presentation will be archived on the site for 90 days.

### **About SUSTOL®**

Heron's lead investigational product candidate, SUSTOL® (granisetron injection, extended release), is being developed for the prevention of both acute- and delayed-onset chemotherapy induced nausea and vomiting (CINV). One of the most debilitating side effects of cancer chemotherapy, CINV is a leading cause of premature discontinuation of treatment. There is only one injectable 5-HT<sub>3</sub> receptor antagonist approved for the prevention of delayed-onset CINV in patients receiving moderately emetogenic chemotherapy (MEC); none are approved for delayed-onset CINV in patients receiving highly emetogenic chemotherapy (HEC). SUSTOL contains the 5-HT<sub>3</sub> receptor antagonist granisetron formulated in the Company's proprietary Biochronomer® polymer-based drug delivery platform, which has been shown in clinical studies to maintain therapeutic drug levels of SUSTOL for up to five days with a single subcutaneous injection. Currently available intravenous and oral formulations of granisetron are approved only for the prevention of acute-onset CINV. Granisetron was selected for SUSTOL because it is widely prescribed by physicians based on a well-established record of safety and efficacy.

### **About HTX-019 for Chemotherapy Induced Nausea and Vomiting**

HTX-019 is a proprietary intravenous formulation of aprepitant, an NK<sub>1</sub> receptor antagonist. HTX-019 does not contain polysorbate 80, which may cause hypersensitivity reactions in some patients. At present, there is only one intravenous NK<sub>1</sub> receptor antagonist approved in the U.S. for the prevention of CINV. NK<sub>1</sub> receptor antagonists are always used in combination with a 5-HT<sub>3</sub> receptor antagonist for the prevention of CINV.

### **About HTX-011 for Post-Operative Pain**

HTX-011 is a combination of local anesthetic bupivacaine and the anti-inflammatory meloxicam in a novel formulation utilizing the proprietary Biochronomer polymer-based drug delivery platform. In an animal model of post-surgical pain, HTX-011 significantly reduced pain through 72 hours.

### **About Heron Therapeutics, Inc.**

Heron Therapeutics, Inc. (formerly A.P. Pharma, Inc.) is a biotechnology company using its proprietary technology and innovative efforts to develop products to address unmet medical needs. The Company's proprietary Biochronomer polymer-based drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by extending the duration of action of known active ingredients. The Company's product development program also focuses on identifying new delivery methods and formulations utilizing known compounds that may expand or extend the therapeutic effort, or eliminate the drawbacks of current therapies.

### **Forward Looking Statements**

This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include those associated with the timing of completion of the HEC study, and the results thereof, and the NDA resubmission for SUSTOL, potential regulatory approval of SUSTOL and the timing for such approval, if approved at all; risks relating to progress in research and development of HTX-019, HTX-011 and our other product candidate programs, including the timing of planned toxicology and clinical studies; the risk that safety and efficacy data from our clinical studies may not warrant further development of our product candidates, risks related to the launch and acceptance of new products generally; risks related to our financial position and our ability to raise additional capital to fund operations if necessary or to pursue additional business opportunities; risks related to strategic business alliances we may pursue or the potential acquisition of other products or technologies and other risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission. We caution investors that forward-looking statements reflect our analysis only on their stated date. We do not intend to update them except as required by law.

Source: Heron Therapeutics, Inc.

### **Heron Therapeutics, Inc.**

#### **Investor Relations Contact:**

Jennifer Capuzelo, 858-703-6063

Sr. Manager, Investor Relations

[icapuzelo@herontx.com](mailto:icapuzelo@herontx.com)

or

**Corporate Contact:**

Barry D. Quart, 650-366-2626

Pharm D., Chief Executive Officer